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Abstract: COVID-19 is known as one of the deadliest pandemics of the century. The rapid spread
of this deadly virus at incredible speed has stunned the planet and poses a challenge to global
scientific and medical communities. Patients with COVID-19 are at an increased risk of co-morbidities
associated with liver dysfunction and injury. Moreover, hepatotoxicity induced by antiviral therapy
is gaining importance and is an area of great concern. Currently, alternatives therapies are being
sought to mitigate hepatic damage, and there has been growing interest in the research on bioactive
phytochemical agents (nutraceuticals) due to their versatility in health benefits reported in various
epidemiological studies. Therefore, this review provides information and summarizes the juncture
of antiviral, immunomodulatory, and hepatoprotective nutraceuticals that can be useful during the
management of COVID-19.
Keywords: COVID-19; coronavirus; ACE2; hepatic dysfunctions; hepatoprotective agents;
nutraceuticals; SARS-CoV-2
1. COVID-19: From Outbreak to Pandemic
The Coronavirus Disease 19 (COVID-19) is a highly infectious disease caused by a novel
coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [1] (Figure 1A).
The COVID-19 disease, which has infected millions and shocked the planet, emerges from the animal
kingdom. Since December 2019, the first case of coronavirus disease (COVID-19) resulted from zoonotic
transmission from the seafood and live wild animal market in Wuhan, China. As of 12 December 2020,
approximately 72 million infections and more than 1,610,684 deaths have been reported, and these
statistics are likely to be higher due to inadequate monitoring in parts of the world and asymptomatic
carriers [2–4] (Figure 1B). The SARS-CoV-2 pandemic can be regarded as the largest global public
health disaster since the onset of the 1918 pandemic.
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Figure 1. Global COVID-19 pandemic. (A); SARS-CoV-2 structure (B); Schematic representation of 
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The number of total COVID-19 cases and deaths associated to COVID-19 was derived from 
Worldometer. Information obtained from https://www.worldometers.info/coronavirus/ on 12 
December 2020.  
SARS-CoV-2 primarily causes respiratory symptoms, including flu-like symptoms and 
interstitial pneumonia, which may further progress into fatal Acute Respiratory Distress Syndrome 
(ARDS) condition [5,6]. However, other organs, particularly the liver, heart, and kidneys, are also 
affected, resulting in multi-organ failure and death in some patients [6]. Higher incidences of 
aminotransferases in and/or bilirubin were reported in COVID-19 patients to a varying degree. 
Moreover, several COVID-19 patients have experienced some type of liver injury, particularly those 
with serious or critical cases [7]. This prompted hepatologists to collaborate with other physicians, 
such as internal medicine and emergency departments, to protect the health status and avoid the 
adverse effects of COVID-19 in people with liver disease. Given the global burden of chronic liver 
disease, this pandemic could further worsen the treatment of patients at risk [8]. This review aims to 
gather information on medicinal plants and nutraceuticals with hepatoprotective activity, which can 
protect against the hepatic damage caused by COVID-19 and antiviral drugs.  
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SARS-CoV-2 primarily causes respiratory symptoms, including flu-like symptoms and interstitial
pneumonia, which may further progress into fatal Acute Respiratory Distress Syndrome (ARDS)
condition [5,6]. However, other organs, particularly the liver, heart, and kidneys, are also affected,
resulting in multi-organ failure and death in some patients [6]. Higher incidences of aminotransferases in
and/or bilirubin were reported in COVID-19 patients to a varying degree. Moreover, several COVID-19
patients have experienced some type of liver injury, particularly those with serious or critical cases [7].
This prompted hepatologists to collaborate with other physicians, such as internal medicine and
emergency departments, to protect the health status and av id he adverse effects of COVID-19 in
people with liv r disease. Given the global burden of chronic liver disease, this pa demic could further
worsen the treatment of patients at risk [8]. This review aims to gather information on medicinal plants
and nutraceuticals with hepatoprotective activity, which can protect against the hepatic damage caused
by COVID-19 and antiviral drugs.
2. Pathogenesis of COVID-19
Coronaviruses are single-stranded RNA viruses known to cause human respiratory tract or animal
intestinal infection [9–11] (Figure 2A). Primarily, there are four main types, including α-coronavirus,
β-coronavirus, δ-coronavirus, and γ-coronavirus [12]. Six coronaviruses, including SARS-CoV
Molecules 2020, 25, 5905 3 of 17
(Severe Acute Respiratory Syndrome CoV) and MERS-CoV (Middle East Respiratory Syndrome
CoV), were reported to cause illness in humans prior to SARS-CoV-2 [13]. Similar to SARS-CoV and
MERS-CoV, SARS-CoV-2 belongs to β-coronavirus. SARS-CoV-2 and SARS have a genome sequence
homology of approximately 79% and is more closely related to SARS-like bat coronaviruses than
SARS-CoV [14]. The spike protein recognizes and binds to the receptor and invades the host cell via
clathrin-mediated endocytosis [15]. After internalization, the virus manipulates the cells’ reproductive
machinery to produce more copies to infect other cells. SARS-CoV-2 also utilizes the cofactors,
Furin and transmembrane proteases, serine 2 (TMPRSS2), protein cleaving enzymes, to cleave viral
S-protein and further facilitate the virus-cell fusion [16,17]. As revealed in structure model analysis,
SARS-CoV-2 binds to Angiotensin I Converting Enzyme 2 (ACE2), a host receptor, with more than a
10-fold higher affinity as compared to SARS-CoV [18] (Figure 2B). These findings explain the greater
propagation capacity of SARS-CoV-2 in humans relative to SARS-CoV and the higher number of
reported cases of COVID-19 relative to SARS-CoV infection [19]. The precise mechanism by which
SARS-CoV-2 influences humans via S-protein binding to ACE2, the association intensity for the danger
of human transmission, and how SARS-CoV-2 causes organ damage remains unclear, and further
studies are required.
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Figure 2. Schematic diagram showing the potential mechanisms of liver injury and abnormality in liver.
(A); COVID-19 infection through the respiratory tract. (B); SARS-CoV-2 binds via its spike proteins to
target cells receptor angiotensin-converting enzyme II (ACE2). (C); Liver function impairment with a
mild-to-moderate increase of liver function enzymes level in the bloodstream.
. Evidence for the Involve e t of iver i I -19 I f cti s
arly servational studies have s o n l i i i , i l i
transferase, alanine transferase, and total bilirubin in COVID-19 patients [20–27] (Figure 2 ). t
c nducted by Chen et al. (2019) showed that more an a third of pa ients with COVID-19 have
some liver functi n test abnormalities [25]. It is uncertain if these laboratory test variatio s are linked
with a o rer prog osis. In another study of 1099 patients from 552 hospit ls, Guan and colleagues
found elevated AST levels in 12 (18.2 percent) pa ients with on-serious disease and 56 (39.4 percent)
ti t it s r i s [ ]. In co parison, the proportion of pathological ALTs i se er c s s
( . ) as higher than in moderate cases (19.8%). Correspondingly, Huang et al. recorded t at
the proportion of ICU patients with liver damage (61.5%) was higher than non-ICU patients (25.0%)
(25.0%) [24]. Recent clinical trials of COVID-19 suggest that elevated transaminases, elevated bilirubin,
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prolonged prothrombin period, hypoproteinemia, and intensity of blood test abnormalities can predict
a worse outcome [28].
4. Mechanism of Liver Injury in COVID-19
The exact mechanism of COVID-19 mediated liver injury is not fully known. In the following
sections, various putative mechanisms involved in underlying hepatic injury are presented (Figure 3).
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4.1. Direct Effect of COVID-19 on Liver
As previously discussed, SARS-CoV-2 uses the ACE2 receptor for entry into the host cells,
where the lung is the main target for infection. Reports from RNA-seq analysis have confirmed the
expression of the ACE2 receptor in the liver. Studies have shown the expression of ACE2 receptor on
liver tissues [29]. Furthermore, liver histology of patients infected with COVID-19 reveals microvascular
steatosis, multinuclear syncytial hepatocytes, and moderate lobular and portal activity [30]. Moreover,
mitochondrial swelling, endoplasmic reticulum dilatation, glycogen degradation, and damaged
cell membranes are demonstrated by electron microscopy. These microscopic and ultrastructural
characteristics co-occur with the SARS-CoV-2’s cytopathic influence on hepatocytes, suggesting its role
for the viral replication within liver cells [31].
4.2. Cytokine Storm Mediated Hepatic Damage
It is observed that the host body activates an immune response against SARS-CoV-2 infection
to facilitate virus clearance and induce a sustained adaptive immune response. Moreover,
serologic analysis has shown elevated levels of Th17, CD8+ T-cells, IL-2, IL-6, IL-10, TNF-α, GM-CSF,
MCP-1, and macrophage inflammatory protein 1 α in patients with severe COVID-19 infection,
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as compared to those in control [24,32–34]. Understandably, these SARS-CoV-2 associated cytokine
storms can damage many organs, including the liver and gut. Many patients eventually died following
organ failure [35]. In a recent meta-analysis, the prevalence of chronic liver disease (CLD) patients
(73 studies, 24,299 patients) was 3% among all COVID-19 patients [36]. The prevalence of CLD patients
was similar in COVID-19 positive and negative populations (pooled OR 0.79 [95% CI 0.60, 1.05],
p = 0.10). The presence of CLD was significantly associated with more severe COVID-19 infection
(pooled OR 1.48 [95% CI 1.17, 1.87], p = 0.001) and overall mortality (pooled OR 1.78 [95% CI 1.09, 2.93],
p = 0.02) [36].
4.3. Hypoxia Associated Liver Damage
Extensive release of cytokines by the immune system in response to viral infection often results
in sepsis symptoms, which caused mortality in 28% of COVID-19 cases [3]. Sepsis is generally
referred to as the dysregulated immune response to an infection that results in multiple organ
dysfunction [37]. The pathophysiology of sepsis-associated liver injury involves hypoxic liver injury
due to several factors, including ischemia and shock, cholestasis, and overwhelming inflammation [38].
It is observed that sepsis is not uncommon in patients with existing liver cirrhosis [39], suggesting that
pneumonia associated hypoxia is one of the most significant factors causing secondary liver injury in
COVID-19 patients.
4.4. Antiviral Induced Hepatotoxicity
Microvascular steatosis and mild lobular and portal activities in postmortem biopsies reveal
that liver injury is either caused by SARS-CoV-2 infection or drug-induced toxicity [30]. In another
study, it was observed that antiviral therapies, including lopinavir/ritonavir used for the treatment of
COVID-19, induces liver injury in patients [40]. Therefore, hepatic enzyme defects arose following the
usage of a hepatotoxic medication; and antiviral induced damage may first be verified or removed.
4.5. Antipyretics Induced Hepatotoxicity
Many affected people were administered with antipyretic agents for fever relief during the
COVID-19 outbreak. Many of these medicines include acetaminophen, a medication believed to inflict
serious harm to the liver and/or trigger liver failure [30]. Acetaminophen is also known as APAP
(acetyl-para-aminophenol) in the USA and paracetamol in Europe, is one of the most widely used
antipyretics and analgesics medications in the world [41].
4.6. Pre-Existing Liver Disease Leads to Worst COVID-19 Outcome
Due to systemic immunodeficiency, patients with chronic liver disease and cirrhosis may have
a higher risk of COVID-19 infections [42]. Moreover, a post-transplant patient is at higher risk
due to immunosuppressive therapy [43,44]. However, the relationship between underlying liver
disease and COVID-19 has not been fully studied. Patients with cirrhosis are at an increased risk
of decompensation or development of acute-on-chronic liver failure when coupled with a bacterial,
fungal, or viral infection [45,46]. Co-morbidities, including coronary artery disease, cerebrovascular
disease, and chronic obstructive pulmonary disease, are more prevalent in hospitalized patients with
severe/critical illnesses from COVID-19, and these patients are more likely to manifest abnormal liver
chemistries [47]. Therefore, special attention should be paid to monitoring hepatic changes triggered
by COVID-19 in patients with a pre-existing history of liver disease (especially older patients).
5. Hepatoprotective Agents
Most of the drugs are metabolized in the liver. As a result, liver injury can occur even though
they are consumed for therapeutic purposes [48]. Since liver injury may result in fatty liver, hepatitis,
fibrosis, cirrhosis, and cancer, this is considered as a serious health concern. Accumulated studies
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have reported that herbal compounds possess numerous medicinal properties. Natural products and
nutraceuticals have shown potent therapeutic activity in liver injuries caused by several toxicants
and drugs [49–53]. This section summarizes selective natural bioactive nutraceuticals exhibiting
the hepatoprotective activity and pays specific attention to toxicants/antiviral induced liver injury
(Figure 4). Few of these have shown potent antiviral activities and may be used in the future as possible
options for the COVID-19 treatment
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5.1. Silybum Marianum
il marianum belongs to the Asteraceae family and is native to the Mediterranean region. It is
commonly known as milk thistle. This plant has thorny branches and milky sap, with oval leaves of
up to 30 cm. The flowers are light pink in colors and can be up to 8 cm in diameter [54]. This plant is
grown in Hungary, China, and South America. In Mexico, milk thistle is consumed as a nutritional
substitute [55]. Silymarin is a naturally occurring compound found in Silybum marianum and is
most notably composed of numerous flavolignans, including silybin, silydianin, and silychristine.
Silybin constitutes approximately 50% to 70% of silymarin extracts. This plant possesses several
pharmacological activities and is used to treat disorders related to the liver, gall bladder, and spleen [56].
Notably, because of its antioxidant, anti-inflammatory, and anti-fibrotic activities, silymarin is probably
the most commonly used natural compound for hepatic disease care worldwide [57]. Most importantly,
its medicinal property has been explored as hepatoprotective for supportive therapy in case of hepatic
dysfunctions such as hepatitis, cirrhosis, and fatty liver [58,59]. Moreover, studies have shown that
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Silybum marianum is very potent against stress induced by toxicants, including poisonous mushrooms,
alcohol, and toxic chemicals [60]. Bioactive components isolated from Silybum spp., silymarin,
showed therapeutic benefits in acute and chronic viral, alcohol, and chemically induced hepatitis [61].
Silymarin is the most frequently used natural compound for treating hepatic diseases worldwide due
to its antioxidant, anti-inflammatory, and anti-fibrotic activities. Inhibition of cyclooxygenase cycle,
leukotrienes, and free radical production contribute to its cytoprotective effects in liver [62].
Silymarin has also been known to increase protein synthesis in hepatocytes [57]. Owing to
its phenolic existence, it can give electrons to stabilize free radicals and reactive oxygen
molecules [63]. Silymarin also modulates intracellular glutathione, which inhibits membranes from
lipid peroxidation [64]. Silymarin also has antiviral effects as it affects RNA and DNA synthesis [65].
Eurasil 85 is a strong oral bioavailable silymarin formulation with potent antioxidant activity are found
in clinical studies, and co-administration with several antiretrovirals has been shown to be safe [66,67].
Although the use of silymarin in the management of hepatic dysfunctions remains a historical interest,
its utility in the management of SAR-COV-2 induced liver dysfunction should be explored [68].
5.2. Solanum Nigrum
Solanum nigrum iscommonlyknownas“Blacknightshade”andisoftencultivatedinopen, wildtemperate
climate regions [69–71]. This also constitutes food crops in several developing countries [72]. Solanum nigrum
has numerous medicinal properties [73]. In traditional medicine, plant leaves have reportedly been used
to treat many illnesses, including seizures, asthma, nausea, ulcers, vomiting, diarrhea, some eye infections,
and jaundice [74,75]. The extracts contain many polyphenolic compounds, such as phenolic acids and
flavones [76]. This herb is used as a potential hepatoprotective agent [69–71]. It exhibits several antioxidant
activities and is known to inhibit lipid peroxidation as a means for their mechanism of action [77,78].
Aqueous extract of S. nigrum has been shown to reduce hepatic enzymes ALT, AST, and ALP significantly.
Moreover, this inhibits bilirubin’s level and scavenge the free radicals production, as observed in CCL4 induced
hepatic damage in rats [79]. The antioxidant activity may be attributable to the polyphenolic compounds’
existence in stems and leaves [80].
5.3. Cichorium Intybus
The plant Cichorium intybus, commonly known as “chicory”, is indigenous to Western Asia,
Egypt, North America, and Europe [81]. This displays several therapeutic properties including
anti-microbial [82,83], immunomodulatory [84], antihepatotoxic [85–87] and anti-hypertiglycemia
activities [88]. Chichorium intybus extract showed remarkable antioxidative effects via inhibition of
thiobarbituric acid reactive substances production [89]. Notably, it has been used in many liver tonics
for the ailment of the liver and digestive disorders [90]. The root extract of C. intybus has shown
anti-hepatotoxic activity against CCL4-induced hepatic damage as demonstrated by decreased levels
of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin in treated groups
as compared to control groups [91]. Interestingly, Zhang et al. (2014) studied the anti-hepatitis activity
of chicoric acid isolated from Chichorium intybus leaves and observed that it can block the viral protein
and DNA synthesis [92].
5.4. Allium Sativum
Allium sativum has been used for more than 5000 years and is commonly known as garlic.
Allium sativum is used as a spice and has numerous medicinal properties. The active components present
in this plant are diallyl thiosulfinate and diallyl disulfide. Studies have reported that pretreatment
with extracts restored antioxidant enzyme levels in GalN/LPS-treated hepatitis in animal models [93].
Furthermore, it is known to attenuate the nitric oxide-induced oxidative stress, and lipid peroxidation
in CCL4 treated mice [94]. Garlic oil has also reduced serum AST, ALT, alkaline phosphatase (ALP),
and gamma-glutamyl transferase (GGT) levels in CCL4-induced hepatotoxicity [95]. It has diverse
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pharmacological activities, including antibacterial, antiviral, antioxidant effects, anti-mutagenic,
and immune-modulatory properties [96,97].
5.5. Glycyrrhiza Glabra
Glycyrrhiza glabra, commonly known as licorice, is native to the Mediterranean region, Western Asia
and Europe. This plant is a very effective treatment for chest disease and asthma [56]. Studies have
shown hepatoprotective activity of G. glabra in CCL4 induced hepatic damage. Following the oral
administration, the level of hepatic iNOS, COX2, and TNF-alpha were significantly reduced in the
treated group compared to the control group [98]. In another study, Kimura et al. showed that G. glabra
is effective in attenuating the serum AST and ALT levels [99]. Glycyrrhizin, is a triterpenoid saponin,
predominantly present in plant roots and possesses numerous pharmacological activities [100–102].
Interestingly, several studies have shown that glycyrrhizin exhibits potent activity against various
human viruses [103–116]. Studies have shown the glycyrrhizin is used alone or in combination with
other medications to combat coronavirus infections [117]. Recently, one study showed its ability to
bind ACE2 that represses the SARS-CoV-2 receptor. Thus, targeting of ACE2 may also be very useful
to prevent diffusion out of the virus from infected cells and invading new cells [118].
5.6. Phyllanthus Amarus
Phyllanthus amarus is a small plant and is commonly found in tropical regions and is used in many
traditional medicines due to its diverse pharmacological activities [119]. Lignan phyllanthin, one of
its essential bioactive constituents, has shown very potent activity as a hepatoprotective agent [120].
Histopathological analysis revealed that ethanolic extract of P. amarus attenuates the generation of
intracellular ROS by enhancing the antioxidant levels against aflatoxin B1-induced hepatotoxicity [121].
Furthermore, an aqueous extract of P. amarus has been shown to inhibit HBV DNA polymerase
activity as seen in in vitro experimental conditions, suggesting its potential use for viral infections
in the liver [122]. Phytochemical screening of P. muellarianus, displayed the presence of several
bioactive ingredients such as furosin, isoquercetin, phaselic acid, corilagin, nitidine, geranin, and gallic
acid [123,124]. Aqueous extract of the P. muellarianus leaf has shown hepatoprotective activity against
damage induced by p-acetaminophen in swiss albino mice [125]. It was observed that extract (p > 0.05)
significantly attenuated acetaminophen-mediated alterations in ALT, alkaline phosphatase (ALP), AST,
albumin (ALB), and total bilirubin (TB). Gallic acid, a well-known antioxidant agent, was documented
to reverse AST, ALT, and ALP in acetaminophen-induced liver toxicity [126].
5.7. Withania Somnifera
Withania somnifera belongs to the family of Solanaceae and is commonly known as ashwagandha,
Indian ginseng, or Winter cherry. Multiple parts of this medicinal plant, such as leaves, fruits, and stems,
have therapeutic effects [127]. The popular bioactive ingredients present in this are withaferin A
and withanolides. Several studies have shown the hepatoprotective activity of this plant without
toxicity [127,128]. Withaferin A performs a crucial function as antiviral agents against several viruses,
including HIV-1 [129], HPV [130], HSV [131], and infectious bursal diseases virus (IBDV) [131]. In a
recent study, it has been reported that withaferin-A and withanone could bind and stably interact with
the catalytic site of TMPRSS2, suggesting their use in the blocking of COVID-19 viral entry into host
cells [132].
5.8. Curcuma Longa
Curcuma longa is a very famous spice native to India and Southeast Asia. This plant has diverse
pharmacological activity, including antibacterial, antifungal, antiviral, and anticancer activities [133].
Curcumin (diferuloylmethane), a polyphenol present in this plant’s rhizome, is responsible for its
therapeutic activity [134,135]. The hepatoprotective function of curcumin depends primarily on its
strong anti-inflammatory and antioxidant effects. It also exhibits immunomodulatory activity by
Molecules 2020, 25, 5905 9 of 17
suppressing the production of cytokines IFN-gamma, ILs, and TNF-alpha. Curcumin is a very effective
blocker of NF-kappa B and inhibits the synthesis of iNOS [136–138]. Research has also shown that
curcumin inhibits hepatic stellate cell activation and collagen expression. Moreover, it has shown
hepatoprotective effects in thioacetamide-induced liver injury and fibrosis [139]. Curcumin has also
been reported to conduct antiviral activities against a large variety of viruses, including HIV-1, HSV-2,
HPV and hepatitis virus [140,141].
5.9. Other Hepatoprotective Agents
Capparis spinosa, generally found in west and Central Asia, is commonly used as a cooking flavoring
agent [142]. Several traditional medicines utilize this plant for the treatment of liver diseases [143].
This possesses numerous bioactivities, including antioxidant, anticancer, and antibacterial properties.
It has been demonstrated that polyphenol present in the plant is responsible for its therapeutic activity.
Liv-52, an Indian herbal preparation for liver disorders, also contains Capparis spinosa, an essential
constituent [144]. Studies suggest that Liv-52 showed significant therapeutic effects in cirrhotic
patients [144]. Additionally, the chemical constituent p-methoxy benzoic acid, from the aqueous
extract of C. spinosa, expresses potent hepatoprotective activity against paracetamol and CCL4-induced
hepatotoxicity [145].
Aquilaria agallocha has several properties, including pharmacological effects, and shows anticancer,
antioxidant, anti-inflammatory, antidiabetic, analgesic, antipyretic, laxative, antidiabetic, antimicrobial,
antibacterial, and anticonvulsant protective activities [146]. The hepatoprotective effects of the ethanolic
extract of A. agallocha leaves in PCM-induced hepatotoxicity in Sprague–Dawley (SD) rats show a
substantial decrease in AST, ALP, ALT, lactate dehydrogenase (LDH), CHL, TB, and an increase in
ALB, total protein concentration, and prevention of PCM-induced histopathological changes in the
liver [147].
Dodonaea viscosa belongs to the soapberry family and is widely distributed in the subtropical,
warm, tropical, temperate regions of Africa, the Americas, Australia, and Southern Asia. Aqueous:
methanolic (70:30) leaves extract of D. viscosa has shown to exhibit the hepatoprotective activity by
reducing the serum level of TAG, total cholesterol, LDL-C, HDL-CHL, ALT, and AST compared
to experimental control sample [148]. Another plant Salix caprea, referred to as goat willow, is a
predominant species of willow in Europe and western/central Asia [149]. The detailed knowledge of
various natural compounds’ hepatoprotective activity has been summarized in the review [150].
Ethanolic extract of Salix subserrata has shown significant hepatoprotective activity in CCl4-induced
liver toxicity [149] by decreasing serum enzymes levels and reversing hepatic tissue damage caused by
CCl4. Studies have shown that the hepatoprotective activity of ethanolic Pandanus odoratissimus roots
extracts in PCM-induced hepatotoxicity in rats resulted in a substantial decrease in the higher levels of
serum marker enzymes [151]. Another plant named Alocasia indica, commonly cultivated especially
in West Bengal, Assam, Maharashtra, and Southern India, has been assessed for hepatoprotective
activity in CCL4-induced hepatic injury in male Albino Wistar rats [152]. It has been reported
that the antioxidant activity of this plant has the potential for designing drugs for liver diseases.
Opuntia ficus-indica, another plant, is a cactus species that are commonly distributed in the arid and
semiarid parts of the world and is believed to have originated from Mexico. Aqueous extract (2 mL/kg)
from the cactus leaves (cladodes) has shown potent hepatoprotective activity in CCl4-induced toxicity
in Wistar male rats by decreasing AST and ALT levels [153]. The use of these natural phytoagents or
nutraceuticals alone or in combination may protect the liver and modulates coronavirus infection,
and provide recommendations for further study.
6. Conclusions
The COVID-19 pandemic has resulted in a global crisis in public health. As noted in COVID-19
patients, liver injury is very common, caused by either direct or indirect damage to organs, including the
overshooting inflammatory response. Importantly, the drug-induced liver injury should not be
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overlooked during coronavirus infection treatment and should be carefully studied. Ultimately, it is
imperative to find alternative methods for hepatoprotection. This review provides information on the
medicinal plants used for various hepatic disorders over several decades. It also highlights the pathways
that these plant-based medicines can seek to reduce the burden of disease. The potential efficacy of
these bioactive nutraceuticals should be explored in COVID-19 patients and at-risk populations.
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